According to a recent real-world cohort study, use of #immunoglobulin replacement therapy for #MultipleMyeloma #MMsm decreases the likelihood of developing infections and is associated with significant reductions in #hypogammaglobulinemia: ow.ly/opap50WIRn1

Importing Inflation: The proposed U.S. #tariff on #pharmaceutical imports would drive up costs immensely. An analysis revealed that the 25% tariff is expected to increase #drug costs by $51 billion annually and drive up prices by as much as 12.9%.

Subcutaneous #isatuximab delivered via an on-body injector was found to be noninferior to IV isatuximab plus #pomalidomide and #dexamethasone in patients with R/R #MultipleMyeloma #MMsm, with both methods resulting in comparable ORR and 12-month PFS: ow.ly/zJCh50WM6cl

See what's to come in the next issue! Below, Aaron Gerds MD, MS shares issue highlights, including a look at the clinician's role within patient support groups, the link between #GLP1s and #hematologic diseases, the growth of #hematology in #Pakistan, and more 🩸 ow.ly/Lltw50WMcRj

According to findings published in Blood Journals Portfolio, adding #mogamulizumab to CHOP significantly improved one-year progression-free survival in patients with aggressive adult #Tcell #leukemia #lymphoma, a population that is often ineligible for #alloHCT: ow.ly/mMxu50WN4k0

APPs on the Front Lines: #AdvancedPracticeProviders (APPs) are an integral part of the #healthcare workforce. A recent report found that APPs make up 40.6% of the health care workforce. The report noted that APPs and #physicians may soon make up equal parts of the labor force.

How would you proceed to diagnosis in a patient with macrocytic anemia, Coombs-negative hemolysis, and pulmonary embolism? Read the September 2025 "You Make The Call" article from ASH Clinical News to find out: ow.ly/W7Xw50WPPXE Aaron Gerds MD, MS @ASH_Hematology

According to new long-term data, among patients with advanced-stage, asymptomatic low-tumor-burden #FollicularLymphoma, early #rituximab monotherapy delayed the TTNT to more than 15 years, compared with less than six years seen with watchful waiting: ow.ly/luEa50WRTVZ

Despite findings from the phase III STARGLO study showing an improvement in OS, a CR letter issued by the #FDA stated there was not sufficient evidence to support a proposed second-line indication of #glofitamab-gxbm for R/R transplant-ineligible #DLBCL: ow.ly/8YWU50WTR3K

The #FDA recently approved #linvoseltamab for the treatment of R/R #MultipleMyeloma #MMsm in adult patients who have received four or more prior lines of therapy following results from the LINKER-MM1 trial, which found a 70% ORR and a 45% CR rate: ow.ly/y8pA50WTRxC

Transparency Unlocked: Transparency of the #FDA approval process may be increasing. Recently, the FDA made more than 200 complete response letters highlighting safety and efficacy concerns accessible to the public.

Phase III date indicate that #avatrombopag is an effective oral treatment for #pediatric patients with a confirmed diagnosis of #ImmuneThrombocytopenia #ITP, with 28% and 81% of patients meeting the primary and alternative primary endpoints, respectively: ow.ly/v9N250WWMEp

Pregnancy Outcomes in SCT: Urinary tract infection (UTI) in #pregnancy may be influenced by #SickleCell trait (SCT). A retrospective data analysis found that 11.7% of patients with SCT and 7.1% of patients without SCT experienced #UTI.

In patients with treatment-naïve #CLL, MRD-guided therapy with #ibrutinib plus #venetoclax led to greater rates of undetectable MRD, extended PFS, and increased OS than ibrutinib alone or #chemoimmunotherapy, especially among patients with unmutated IGHV: ow.ly/oA2u50WWZZc

In #Uruguay, use of a single-run NGS approach was able to detect both somatic mutations and copy number variants in patients with #MyelodysplasticSyndromes #MDS, ultimately allowing for both improved diagnostic accuracy and optimized workflows: ow.ly/Cfwx50WX9KG

See what's to come in the October issue with Aaron Gerds MD, MS! Issue highlights include a clinical case of a patient with a large #hematoma and multiple comorbidities, an in-depth look at the rare #WHIMsyndrome, the evolution of #hematopathology, and more: ow.ly/nYsx50WXxqA

The IMS-IMWG recently released new recommendations on the definition of high-​risk #MultipleMyeloma, based on the use of genomic tools, to improve identification of patients with high-risk #MMsm and allow clinicians to provide more realistic prognoses: ow.ly/lfv350WXaup

Findings from the BASIS trial reveal that #marstacimab is an effective prophylactic option for patients with #hemophilia A and B, as the therapy led to a 92% reduction in mean ABR among patients who previously received on-demand #clotting factors: ow.ly/RIy850WXbGs

Mantle cell lymphoma treatment isn’t one-size-fits-all. Discover how to personalize care and optimize outcomes in our Oct. 3 webinar moderated by Aaron Gerds MD, MS . Register today: bit.ly/4nWEIli